Description

Ponatinib-d8 is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-Kinase/protease-Formula-C29H19D8F3N6O-Citation–References-[1]O’Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.-CASNumber-1562993-37-6-MolecularWeight-540.61-Compound Purity-99.91-SMILES-O=C(NC1=CC=C(CN2C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C2([2H])[2H])C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C5C=CC=NN54)=C3-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Autophagy;Bcr-Abl;FGFR;PDGFR;Src;VEGFR-Isoform-FGFR1;PDGFRα;VEGFR2/KDR/Flk-1-Pathway-Autophagy;Protein Tyrosine Kinase/RTK-MCE Product type-Isotope-Labeled Compounds